Global and United States Liposomal Doxorubicin Market Report & Forecast 2022-2028

• Description
• Table of Contents
• Table of Figures
• PDF Download

• Description
• Table of Contents
• Table of Figures
• PDF Download

Liposome doxorubicin is a commonly used anthracycline anti-tumor drug, and is one of the first-line drugs for ovarian cancer.

Market Analysis and Insights: Global and United States Liposomal Doxorubicin Market
This report focuses on global and United States Liposomal Doxorubicin market, also covers the segmentation data of other regions in regional level and county level.

Due to the COVID-19 pandemic, the global Liposomal Doxorubicin market size is estimated to be worth US$ 1378.9 million in 2022 and is forecast to a readjusted size of US$ 2152 million by 2028 with a CAGR of 7.7% during the review period. Fully considering the economic change by this health crisis, by Type, 5 ml accounting for % of the Liposomal Doxorubicin global market in 2021, is projected to value US$  million by 2028, growing at a revised % CAGR in the post-COVID-19 period. While by Application, Breast Cancer was the leading segment, accounting for over  percent market share in 2021, and altered to an  % CAGR throughout this forecast period.

Market competition is intense. Johnson & Johnson, Sun Pharmaceutical, CSPC, etc. are the leaders of the industry, and they hold key technologies and patents, with high-end customers. Top 3 accounted for 60.41% market share.

Global Liposomal Doxorubicin Scope and Market Size
Liposomal Doxorubicin market is segmented by region (country), players, by Type and by Application. Players, stakeholders, and other participants in the global Liposomal Doxorubicin market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application for the period 2017-2028.

For United States market, this report focuses on the Liposomal Doxorubicin market size by players, by Type and by Application, for the period 2017-2028. The key players include the global and local players, which play important roles in United States.

Segment by Type, the Liposomal Doxorubicin market is segmented into
    5 ml
    10 ml
    25 ml

Segment by Application, the Liposomal Doxorubicin market is segmented into
    Breast Cancer
    Liver Cancer
    Kidney Cancer
    Multiple Myeloma
    Ovarian Cancer
    Other

Regional and Country-level Analysis
By Region
    North America
        U.S.
        Canada
    Europe
        Germany
        France
        U.K.
        Italy
        Russia
    Asia-Pacific
        China
        Japan
        South Korea
        India
        Australia
        Taiwan
        Indonesia
        Thailand
        Malaysia
        Philippines
        Vietnam
    Latin America
        Mexico
        Brazil
        Argentina
    Middle East & Africa
        Turkey
        Saudi Arabia
        UAE

Competitive Landscape and Liposomal Doxorubicin Market Share Analysis
Liposomal Doxorubicin market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2017-2022. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2017-2022. Details included are company description, major business, company total revenue and the sales, revenue generated in Liposomal Doxorubicin business, the date to enter into the Liposomal Doxorubicin market, Liposomal Doxorubicin product introduction, recent developments, etc.

The major vendors covered:
    Johnson & Johnson
    Sun Pharmaceutical
    CSPC
    Kinyond
    Teva
    Fudan-Zhangjiang
    Zydus Cadila
    TTY Biopharma

 1 Study Coverage
    1.1 Liposomal Doxorubicin Product Introduction
    1.2 Global Liposomal Doxorubicin Outlook 2017 VS 2022 VS 2028
        1.2.1 Global Liposomal Doxorubicin Sales in US$ Million for the Year 2017-2028
        1.2.2 Global Liposomal Doxorubicin Sales in Volume for the Year 2017-2028
    1.3 United States Liposomal Doxorubicin Outlook 2017 VS 2022 VS 2028
        1.3.1 United States Liposomal Doxorubicin Sales in US$ Million for the Year 2017-2028
        1.3.2 United States Liposomal Doxorubicin Sales in Volume for the Year 2017-2028
    1.4 Liposomal Doxorubicin Market Size, United States VS Global, 2017 VS 2022 VS 2028
        1.4.1 The Market Share of United States Liposomal Doxorubicin in Global, 2017 VS 2022 VS 2028
        1.4.2 The Growth Rate of Liposomal Doxorubicin Market Size, United States VS Global, 2017 VS 2022 VS 2028
    1.5 Liposomal Doxorubicin Market Dynamics
        1.5.1 Liposomal Doxorubicin Industry Trends
        1.5.2 Liposomal Doxorubicin Market Drivers
        1.5.3 Liposomal Doxorubicin Market Challenges
        1.5.4 Liposomal Doxorubicin Market Restraints
    1.6 Study Objectives
    1.7 Years Considered

 2 Market by Type
    2.1 Liposomal Doxorubicin Market Segment by Type
        2.1.1 5 ml
        2.1.2 10 ml
        2.1.3 25 ml
    2.2 Global Liposomal Doxorubicin Market Size by Type
        2.2.1 Global Liposomal Doxorubicin Sales in Value, by Type (2017, 2022 & 2028)
        2.2.2 Global Liposomal Doxorubicin Sales in Volume, by Type (2017, 2022 & 2028)
        2.2.3 Global Liposomal Doxorubicin Average Selling Price (ASP) by Type (2017, 2022 & 2028)
    2.3 United States Liposomal Doxorubicin Market Size by Type
        2.3.1 United States Liposomal Doxorubicin Sales in Value, by Type (2017, 2022 & 2028)
        2.3.2 United States Liposomal Doxorubicin Sales in Volume, by Type (2017, 2022 & 2028)
        2.3.3 United States Liposomal Doxorubicin Average Selling Price (ASP) by Type (2017, 2022 & 2028)

 3 Market by Application
    3.1 Liposomal Doxorubicin Market Segment by Application
        3.1.1 Breast Cancer
        3.1.2 Liver Cancer
        3.1.3 Kidney Cancer
        3.1.4 Multiple Myeloma
        3.1.5 Ovarian Cancer
        3.1.6 Other
    3.2 Global Liposomal Doxorubicin Market Size by Application
        3.2.1 Global Liposomal Doxorubicin Sales in Value, by Application (2017, 2022 & 2028)
        3.2.2 Global Liposomal Doxorubicin Sales in Volume, by Application (2017, 2022 & 2028)
        3.3.3 Global Liposomal Doxorubicin Average Selling Price (ASP) by Application (2017, 2022 & 2028)
    3.3 United States Liposomal Doxorubicin Market Size by Application
        3.3.1 United States Liposomal Doxorubicin Sales in Value, by Application (2017, 2022 & 2028)
        3.3.2 United States Liposomal Doxorubicin Sales in Volume, by Application (2017, 2022 & 2028)
        3.3.3 United States Liposomal Doxorubicin Average Selling Price (ASP) by Application (2017, 2022 & 2028)

 4 Global Liposomal Doxorubicin Competitor Landscape by Company
    4.1 Global Liposomal Doxorubicin Market Size by Company
        4.1.1 Top Global Liposomal Doxorubicin Manufacturers Ranked by Revenue (2021)
        4.1.2 Global Liposomal Doxorubicin Revenue by Manufacturer (2017-2022)
        4.1.3 Global Liposomal Doxorubicin Sales by Manufacturer (2017-2022)
        4.1.4 Global Liposomal Doxorubicin Price by Manufacturer (2017-2022)
    4.2 Global Liposomal Doxorubicin Concentration Ratio (CR)
        4.2.1 Liposomal Doxorubicin Market Concentration Ratio (CR) (2017-2022)
        4.2.2 Global Top 5 and Top 10 Largest Manufacturers of Liposomal Doxorubicin in 2021
        4.2.3 Global Liposomal Doxorubicin Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
    4.3 Global Liposomal Doxorubicin Manufacturing Base Distribution, Product Type
        4.3.1 Global Liposomal Doxorubicin Manufacturers, Headquarters and Distribution of Producing Region
        4.3.2 Manufacturers Liposomal Doxorubicin Product Type
        4.3.3 Date of International Manufacturers Enter into Liposomal Doxorubicin Market
    4.4 Manufacturers Mergers & Acquisitions, Expansion Plans
    4.5 United States Liposomal Doxorubicin Market Size by Company
        4.5.1 Top Liposomal Doxorubicin Players in United States, Ranked by Revenue (2021)
        4.5.2 United States Liposomal Doxorubicin Revenue by Players (2020, 2021 & 2022)
        4.5.3 United States Liposomal Doxorubicin Sales by Players (2020, 2021 & 2022)

 5 Global Liposomal Doxorubicin Market Size by Region
    5.1 Global Liposomal Doxorubicin Market Size by Region: 2017 VS 2022 VS 2028
    5.2 Global Liposomal Doxorubicin Market Size in Volume by Region (2017-2028)
        5.2.1 Global Liposomal Doxorubicin Sales in Volume by Region: 2017-2022
        5.2.2 Global Liposomal Doxorubicin Sales in Volume Forecast by Region (2023-2028)
    5.3 Global Liposomal Doxorubicin Market Size in Value by Region (2017-2028)
        5.3.1 Global Liposomal Doxorubicin Sales in Value by Region: 2017-2022
        5.3.2 Global Liposomal Doxorubicin Sales in Value by Region: 2023-2028

 6 Segment in Region Level & Country Level
    6.1 North America
        6.1.1 North America Liposomal Doxorubicin Market Size YoY Growth 2017-2028
        6.1.2 North America Liposomal Doxorubicin Market Facts & Figures by Country (2017, 2022 & 2028)
        6.1.3 U.S.
        6.1.4 Canada
    6.2 Asia-Pacific
        6.2.1 Asia-Pacific Liposomal Doxorubicin Market Size YoY Growth 2017-2028
        6.2.2 Asia-Pacific Liposomal Doxorubicin Market Facts & Figures by Region (2017, 2022 & 2028)
        6.2.3 China
        6.2.4 Japan
        6.2.5 South Korea
        6.2.6 India
        6.2.7 Australia
        6.2.8 Taiwan
        6.2.9 Indonesia
        6.2.10 Thailand
        6.2.11 Malaysia
        6.2.12 Philippines
    6.3 Europe
        6.3.1 Europe Liposomal Doxorubicin Market Size YoY Growth 2017-2028
        6.3.2 Europe Liposomal Doxorubicin Market Facts & Figures by Country (2017, 2022 & 2028)
        6.3.3 Germany
        6.3.4 France
        6.3.5 U.K.
        6.3.6 Italy
        6.3.7 Russia
    6.4 Latin America
        6.4.1 Latin America Liposomal Doxorubicin Market Size YoY Growth 2017-2028
        6.4.2 Latin America Liposomal Doxorubicin Market Facts & Figures by Country (2017, 2022 & 2028)
        6.4.3 Mexico
        6.4.4 Brazil
        6.4.5 Argentina
    6.5 Middle East and Africa
        6.5.1 Middle East and Africa Liposomal Doxorubicin Market Size YoY Growth 2017-2028
        6.5.2 Middle East and Africa Liposomal Doxorubicin Market Facts & Figures by Country (2017, 2022 & 2028)
        6.5.3 Turkey
        6.5.4 Saudi Arabia
        6.5.5 UAE

 7 Company Profiles
    7.1 Johnson & Johnson
        7.1.1 Johnson & Johnson Corporation Information
        7.1.2 Johnson & Johnson Description and Business Overview
        7.1.3 Johnson & Johnson Liposomal Doxorubicin Sales, Revenue and Gross Margin (2017-2022)
        7.1.4 Johnson & Johnson Liposomal Doxorubicin Products Offered
        7.1.5 Johnson & Johnson Recent Development
    7.2 Sun Pharmaceutical
        7.2.1 Sun Pharmaceutical Corporation Information
        7.2.2 Sun Pharmaceutical Description and Business Overview
        7.2.3 Sun Pharmaceutical Liposomal Doxorubicin Sales, Revenue and Gross Margin (2017-2022)
        7.2.4 Sun Pharmaceutical Liposomal Doxorubicin Products Offered
        7.2.5 Sun Pharmaceutical Recent Development
    7.3 CSPC
        7.3.1 CSPC Corporation Information
        7.3.2 CSPC Description and Business Overview
        7.3.3 CSPC Liposomal Doxorubicin Sales, Revenue and Gross Margin (2017-2022)
        7.3.4 CSPC Liposomal Doxorubicin Products Offered
        7.3.5 CSPC Recent Development
    7.4 Kinyond
        7.4.1 Kinyond Corporation Information
        7.4.2 Kinyond Description and Business Overview
        7.4.3 Kinyond Liposomal Doxorubicin Sales, Revenue and Gross Margin (2017-2022)
        7.4.4 Kinyond Liposomal Doxorubicin Products Offered
        7.4.5 Kinyond Recent Development
    7.5 Teva
        7.5.1 Teva Corporation Information
        7.5.2 Teva Description and Business Overview
        7.5.3 Teva Liposomal Doxorubicin Sales, Revenue and Gross Margin (2017-2022)
        7.5.4 Teva Liposomal Doxorubicin Products Offered
        7.5.5 Teva Recent Development
    7.6 Fudan-Zhangjiang
        7.6.1 Fudan-Zhangjiang Corporation Information
        7.6.2 Fudan-Zhangjiang Description and Business Overview
        7.6.3 Fudan-Zhangjiang Liposomal Doxorubicin Sales, Revenue and Gross Margin (2017-2022)
        7.6.4 Fudan-Zhangjiang Liposomal Doxorubicin Products Offered
        7.6.5 Fudan-Zhangjiang Recent Development
    7.7 Zydus Cadila
        7.7.1 Zydus Cadila Corporation Information
        7.7.2 Zydus Cadila Description and Business Overview
        7.7.3 Zydus Cadila Liposomal Doxorubicin Sales, Revenue and Gross Margin (2017-2022)
        7.7.4 Zydus Cadila Liposomal Doxorubicin Products Offered
        7.7.5 Zydus Cadila Recent Development
    7.8 TTY Biopharma
        7.8.1 TTY Biopharma Corporation Information
        7.8.2 TTY Biopharma Description and Business Overview
        7.8.3 TTY Biopharma Liposomal Doxorubicin Sales, Revenue and Gross Margin (2017-2022)
        7.8.4 TTY Biopharma Liposomal Doxorubicin Products Offered
        7.8.5 TTY Biopharma Recent Development

 8 Industry Chain and Sales Channels Analysis
    8.1 Liposomal Doxorubicin Industry Chain Analysis
    8.2 Liposomal Doxorubicin Key Raw Materials
        8.2.1 Key Raw Materials
        8.2.2 Liposomal Doxorubicin Distributors
    8.3 Liposomal Doxorubicin Production Mode & Process
    8.4 Liposomal Doxorubicin Sales and Marketing
        8.4.1 Liposomal Doxorubicin Sales Channels
        8.4.2 Liposomal Doxorubicin Distributors
    8.5 Liposomal Doxorubicin Customers

 9 Research Findings and Conclusion

 10 Appendix
    10.1 Research Methodology
        10.1.1 Methodology/Research Approach
        10.1.2 Data Source
    10.2 Author Details
    10.3 Disclaimer

List of Tables
    Table 1. Liposomal Doxorubicin CAGR in Value, United States VS Global, 2017 VS 2022 VS 2028
    Table 2. Liposomal Doxorubicin Market Trends
    Table 3. Liposomal Doxorubicin Market Drivers
    Table 4. Liposomal Doxorubicin Market Challenges
    Table 5. Liposomal Doxorubicin Market Restraints
    Table 6. Global Liposomal Doxorubicin Sales by Type: 2017 VS 2022 VS 2028 (US$ Million)
    Table 7. United States Liposomal Doxorubicin Sales by Type: 2017 VS 2022 VS 2028 (US$ Million)
    Table 8. Global Liposomal Doxorubicin Sales by Application: 2017 VS 2022 VS 2028 (US$ Million)
    Table 9. United States Liposomal Doxorubicin Sales by Application: 2017 VS 2022 VS 2028 (US$ Million)
    Table 10. Top Liposomal Doxorubicin Manufacturers in Global Market, Ranking by Revenue (2021)
    Table 11. Global Liposomal Doxorubicin Revenue by Manufacturer, (US$ Million), 2017-2022
    Table 12. Global Liposomal Doxorubicin Revenue Share by Manufacturer, 2017-2022
    Table 13. Global Liposomal Doxorubicin Sales by Manufacturer, (K Unit), 2017-2022
    Table 14. Global Liposomal Doxorubicin Sales Share by Manufacturer, 2017-2022
    Table 15. Global Liposomal Doxorubicin Price by Manufacturer (2017-2022) & (USD/Unit)
    Table 16. Global Liposomal Doxorubicin Manufacturers Market Concentration Ratio (CR5 and HHI)
    Table 17. Global Liposomal Doxorubicin by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Liposomal Doxorubicin as of 2021)
    Table 18. Top Players of Liposomal Doxorubicin in Global Market, Headquarters and Distribution of Producing Region
    Table 19. Manufacturers Liposomal Doxorubicin Product Type
    Table 20. Date of International Manufacturers Enter into Liposomal Doxorubicin Market
    Table 21. Manufacturers Mergers & Acquisitions, Expansion Plans
    Table 22. Top Liposomal Doxorubicin Players in United States Market, Ranking by Revenue (2021)
    Table 23. United States Liposomal Doxorubicin Revenue by Players, (US$ Million), 2020, 2021 & 2022
    Table 24. United States Liposomal Doxorubicin Revenue Share by Players, 2020, 2021 & 2022
    Table 25. United States Liposomal Doxorubicin Sales by Players, (K Unit), 2020, 2021 & 2022
    Table 26. United States Liposomal Doxorubicin Sales Share by Players, 2020, 2021 & 2022
    Table 27. Global Liposomal Doxorubicin Market Size by Region (US$ Million): 2017 VS 2022 VS 2028
    Table 28. Global Liposomal Doxorubicin Sales in Volume by Region (2017-2022) & (K Unit)
    Table 29. Global Liposomal Doxorubicin Sales in Volume Forecast by Region (2023-2028) & (K Unit)
    Table 30. Global Liposomal Doxorubicin Sales in Value by Region (2017-2022) & (US$ Million)
    Table 31. Global Liposomal Doxorubicin Sales in Value Forecast by Region (2023-2028) & (US$ Million)
    Table 32. North America Liposomal Doxorubicin Sales in Volume by Country (2017-2028) & (K Unit)
    Table 33. North America Liposomal Doxorubicin Sales in Value by Country (2017-2028) & (US$ Million)
    Table 34. Asia Pacific Liposomal Doxorubicin Sales in Volume by Region (2017-2028) & (K Unit)
    Table 35. Asia Pacific Liposomal Doxorubicin Sales in Value by Region (2017-2028) & (US$ Million)
    Table 36. Europe Liposomal Doxorubicin Sales in Volume by Country (2017-2028) & (K Unit)
    Table 37. Europe Liposomal Doxorubicin Sales in Value by Country (2017-2028) & (US$ Million)
    Table 38. Latin America Liposomal Doxorubicin Sales in Volume by Country (2017-2028) & (K Unit)
    Table 39. Latin Americaa Liposomal Doxorubicin Sales in Value by Country (2017-2028) & (US$ Million)
    Table 40. Middle East and Africa Liposomal Doxorubicin Sales in Volume by Country (2017-2028) & (K Unit)
    Table 41. Middle East and Africa Liposomal Doxorubicin Sales in Value by Country (2017-2028) & (US$ Million)
    Table 42. Johnson & Johnson Corporation Information
    Table 43. Johnson & Johnson Description and Business Overview
    Table 44. Johnson & Johnson Liposomal Doxorubicin Sales (K Unit), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 45. Johnson & Johnson Liposomal Doxorubicin Product
    Table 46. Johnson & Johnson Recent Development
    Table 47. Sun Pharmaceutical Corporation Information
    Table 48. Sun Pharmaceutical Description and Business Overview
    Table 49. Sun Pharmaceutical Liposomal Doxorubicin Sales (K Unit), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 50. Sun Pharmaceutical Product
    Table 51. Sun Pharmaceutical Recent Development
    Table 52. CSPC Corporation Information
    Table 53. CSPC Description and Business Overview
    Table 54. CSPC Liposomal Doxorubicin Sales (K Unit), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 55. CSPC Product
    Table 56. CSPC Recent Development
    Table 57. Kinyond Corporation Information
    Table 58. Kinyond Description and Business Overview
    Table 59. Kinyond Liposomal Doxorubicin Sales (K Unit), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 60. Kinyond Product
    Table 61. Kinyond Recent Development
    Table 62. Teva Corporation Information
    Table 63. Teva Description and Business Overview
    Table 64. Teva Liposomal Doxorubicin Sales (K Unit), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 65. Teva Product
    Table 66. Teva Recent Development
    Table 67. Fudan-Zhangjiang Corporation Information
    Table 68. Fudan-Zhangjiang Description and Business Overview
    Table 69. Fudan-Zhangjiang Liposomal Doxorubicin Sales (K Unit), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 70. Fudan-Zhangjiang Product
    Table 71. Fudan-Zhangjiang Recent Development
    Table 72. Zydus Cadila Corporation Information
    Table 73. Zydus Cadila Description and Business Overview
    Table 74. Zydus Cadila Liposomal Doxorubicin Sales (K Unit), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 75. Zydus Cadila Product
    Table 76. Zydus Cadila Recent Development
    Table 77. TTY Biopharma Corporation Information
    Table 78. TTY Biopharma Description and Business Overview
    Table 79. TTY Biopharma Liposomal Doxorubicin Sales (K Unit), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 80. TTY Biopharma Product
    Table 81. TTY Biopharma Recent Development
    Table 82. Key Raw Materials Lists
    Table 83. Raw Materials Key Suppliers Lists
    Table 84. Liposomal Doxorubicin Customers List
    Table 85. Liposomal Doxorubicin Distributors List
    Table 86. Research Programs/Design for This Report
    Table 87. Key Data Information from Secondary Sources
    Table 88. Key Data Information from Primary Sources
List of Figures
    Figure 1. Liposomal Doxorubicin Product Picture
    Figure 2. Global Liposomal Doxorubicin Revenue, (US$ Million), 2017 VS 2022 VS 2028
    Figure 3. Global Liposomal Doxorubicin Market Size 2017-2028 (US$ Million)
    Figure 4. Global Liposomal Doxorubicin Sales 2017-2028 (K Unit)
    Figure 5. United States Liposomal Doxorubicin Revenue, (US$ Million), 2017 VS 2022 VS 2028
    Figure 6. United States Liposomal Doxorubicin Market Size 2017-2028 (US$ Million)
    Figure 7. United States Liposomal Doxorubicin Sales 2017-2028 (K Unit)
    Figure 8. United States Liposomal Doxorubicin Market Share in Global, in Value (US$ Million) 2017-2028
    Figure 9. United States Liposomal Doxorubicin Market Share in Global, in Volume (K Unit) 2017-2028
    Figure 10. Liposomal Doxorubicin Report Years Considered
    Figure 11. Product Picture of 5 ml
    Figure 12. Product Picture of 10 ml
    Figure 13. Product Picture of 25 ml
    Figure 14. Global Liposomal Doxorubicin Market Share by Type in 2022 & 2028
    Figure 15. Global Liposomal Doxorubicin Sales in Value by Type (2017-2028) & (US$ Million)
    Figure 16. Global Liposomal Doxorubicin Sales Market Share in Value by Type (2017-2028)
    Figure 17. Global Liposomal Doxorubicin Sales by Type (2017-2028) & (K Unit)
    Figure 18. Global Liposomal Doxorubicin Sales Market Share in Volume by Type (2017-2028)
    Figure 19. Global Liposomal Doxorubicin Price by Type (2017-2028) & (USD/Unit)
    Figure 20. United States Liposomal Doxorubicin Market Share by Type in 2022 & 2028
    Figure 21. United States Liposomal Doxorubicin Sales in Value by Type (2017-2028) & (US$ Million)
    Figure 22. United States Liposomal Doxorubicin Sales Market Share in Value by Type (2017-2028)
    Figure 23. United States Liposomal Doxorubicin Sales by Type (2017-2028) & (K Unit)
    Figure 24. United States Liposomal Doxorubicin Sales Market Share in Volume by Type (2017-2028)
    Figure 25. United States Liposomal Doxorubicin Price by Type (2017-2028) & (USD/Unit)
    Figure 26. Product Picture of Breast Cancer
    Figure 27. Product Picture of Liver Cancer
    Figure 28. Product Picture of Kidney Cancer
    Figure 29. Product Picture of Multiple Myeloma
    Figure 30. Product Picture of Ovarian Cancer
    Figure 31. Product Picture of Other
    Figure 32. Global Liposomal Doxorubicin Market Share by Application in 2022 & 2028
    Figure 33. Global Liposomal Doxorubicin Sales in Value by Application (2017-2028) & (US$ Million)
    Figure 34. Global Liposomal Doxorubicin Sales Market Share in Value by Application (2017-2028)
    Figure 35. Global Liposomal Doxorubicin Sales by Application (2017-2028) & (K Unit)
    Figure 36. Global Liposomal Doxorubicin Sales Market Share in Volume by Application (2017-2028)
    Figure 37. Global Liposomal Doxorubicin Price by Application (2017-2028) & (USD/Unit)
    Figure 38. United States Liposomal Doxorubicin Market Share by Application in 2022 & 2028
    Figure 39. United States Liposomal Doxorubicin Sales in Value by Application (2017-2028) & (US$ Million)
    Figure 40. United States Liposomal Doxorubicin Sales Market Share in Value by Application (2017-2028)
    Figure 41. United States Liposomal Doxorubicin Sales by Application (2017-2028) & (K Unit)
    Figure 42. United States Liposomal Doxorubicin Sales Market Share in Volume by Application (2017-2028)
    Figure 43. United States Liposomal Doxorubicin Price by Application (2017-2028) & (USD/Unit)
    Figure 44. North America Liposomal Doxorubicin Sales in Volume Growth Rate 2017-2028 (K Unit)
    Figure 45. North America Liposomal Doxorubicin Sales in Value Growth Rate 2017-2028 (US$ Million)
    Figure 46. U.S. Liposomal Doxorubicin Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 47. Canada Liposomal Doxorubicin Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 48. Europe Liposomal Doxorubicin Sales in Volume Growth Rate 2017-2028 (K Unit)
    Figure 49. Europe Liposomal Doxorubicin Sales in Value Growth Rate 2017-2028 (US$ Million)
    Figure 50. Germany Liposomal Doxorubicin Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 51. France Liposomal Doxorubicin Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 52. U.K. Liposomal Doxorubicin Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 53. Italy Liposomal Doxorubicin Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 54. Russia Liposomal Doxorubicin Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 55. Asia-Pacific Liposomal Doxorubicin Sales in Volume Growth Rate 2017-2028 (K Unit)
    Figure 56. Asia-Pacific Liposomal Doxorubicin Sales in Value Growth Rate 2017-2028 (US$ Million)
    Figure 57. China Liposomal Doxorubicin Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 58. Japan Liposomal Doxorubicin Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 59. South Korea Liposomal Doxorubicin Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 60. India Liposomal Doxorubicin Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 61. Australia Liposomal Doxorubicin Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 62. Taiwan Liposomal Doxorubicin Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 63. Indonesia Liposomal Doxorubicin Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 64. Thailand Liposomal Doxorubicin Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 65. Malaysia Liposomal Doxorubicin Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 66. Philippines Liposomal Doxorubicin Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 67. Latin America Liposomal Doxorubicin Sales in Volume Growth Rate 2017-2028 (K Unit)
    Figure 68. Latin America Liposomal Doxorubicin Sales in Value Growth Rate 2017-2028 (US$ Million)
    Figure 69. Mexico Liposomal Doxorubicin Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 70. Brazil Liposomal Doxorubicin Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 71. Argentina Liposomal Doxorubicin Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 72. Middle East & Africa Liposomal Doxorubicin Sales in Volume Growth Rate 2017-2028 (K Unit)
    Figure 73. Middle East & Africa Liposomal Doxorubicin Sales in Value Growth Rate 2017-2028 (US$ Million)
    Figure 74. Turkey Liposomal Doxorubicin Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 75. Saudi Arabia Liposomal Doxorubicin Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 76. UAE Liposomal Doxorubicin Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 77. Liposomal Doxorubicin Value Chain
    Figure 78. Liposomal Doxorubicin Production Process
    Figure 79. Channels of Distribution
    Figure 80. Distributors Profiles
    Figure 81. Bottom-up and Top-down Approaches for This Report
    Figure 82. Data Triangulation
    Figure 83. Key Executives Interviewed

Liposome doxorubicin is a commonly used anthracycline anti-tumor drug, and is one of the first-line drugs for ovarian cancer.

Market Analysis and Insights: Global and United States Liposomal Doxorubicin Market
This report focuses on global and United States Liposomal Doxorubicin market, also covers the segmentation data of other regions in regional level and county level.

Due to the COVID-19 pandemic, the global Liposomal Doxorubicin market size is estimated to be worth US$ 1378.9 million in 2022 and is forecast to a readjusted size of US$ 2152 million by 2028 with a CAGR of 7.7% during the review period. Fully considering the economic change by this health crisis, by Type, 5 ml accounting for % of the Liposomal Doxorubicin global market in 2021, is projected to value US$  million by 2028, growing at a revised % CAGR in the post-COVID-19 period. While by Application, Breast Cancer was the leading segment, accounting for over  percent market share in 2021, and altered to an  % CAGR throughout this forecast period.

Market competition is intense. Johnson & Johnson, Sun Pharmaceutical, CSPC, etc. are the leaders of the industry, and they hold key technologies and patents, with high-end customers. Top 3 accounted for 60.41% market share.

Global Liposomal Doxorubicin Scope and Market Size
Liposomal Doxorubicin market is segmented by region (country), players, by Type and by Application. Players, stakeholders, and other participants in the global Liposomal Doxorubicin market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application for the period 2017-2028.

For United States market, this report focuses on the Liposomal Doxorubicin market size by players, by Type and by Application, for the period 2017-2028. The key players include the global and local players, which play important roles in United States.

Segment by Type, the Liposomal Doxorubicin market is segmented into
    5 ml
    10 ml
    25 ml

Segment by Application, the Liposomal Doxorubicin market is segmented into
    Breast Cancer
    Liver Cancer
    Kidney Cancer
    Multiple Myeloma
    Ovarian Cancer
    Other

Regional and Country-level Analysis
By Region
    North America
        U.S.
        Canada
    Europe
        Germany
        France
        U.K.
        Italy
        Russia
    Asia-Pacific
        China
        Japan
        South Korea
        India
        Australia
        Taiwan
        Indonesia
        Thailand
        Malaysia
        Philippines
        Vietnam
    Latin America
        Mexico
        Brazil
        Argentina
    Middle East & Africa
        Turkey
        Saudi Arabia
        UAE

Competitive Landscape and Liposomal Doxorubicin Market Share Analysis
Liposomal Doxorubicin market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2017-2022. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2017-2022. Details included are company description, major business, company total revenue and the sales, revenue generated in Liposomal Doxorubicin business, the date to enter into the Liposomal Doxorubicin market, Liposomal Doxorubicin product introduction, recent developments, etc.

The major vendors covered:
    Johnson & Johnson
    Sun Pharmaceutical
    CSPC
    Kinyond
    Teva
    Fudan-Zhangjiang
    Zydus Cadila
    TTY Biopharma